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ing cardiopulmonary bypass (CPB).1,2 When compared
with other options, the effect of r-hirudin is achieved
immediately, the renal elimination is fast, and, because
of its protein structure, r-hirudin does not cross-react
with heparin-induced antibodies as described in
approximately 10% of patients given the heparinoid
danaparoid sodium (Orgaran).3 The use of r-hirudin
during CPB necessitates close monitoring of its con-
centration via measurement of the ecarin clotting time
(ECT). However, the only available ready-to-use point-
of-care assay for this test, the ECT card for the TAS
analyzer (Cardiovascular Diagnostics Inc, Raleigh, NC)
is only available for investigational use, although it has
been used during emergency CPB.1 The originally
described method4,5 has drawbacks, because both expe-
rience in the handling of the device and close attention
during the performance of the test are necessary.
Moreover, precise measurement of the ECT depends on
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sufficient (60%) prothrombin and fibrinogen levels,5,6
particularly for monitoring higher concentrations (>2
µg/mL) of r-hirudin. During prolonged perfusions,
however, apart from the hemodilution on the CPB sys-
tem, procoagulants and platelets are progressively con-
sumed on the foreign surfaces.
We adapted the original method of ECT measure-
ment to the commonly used ACT II device (Medtronic,
Inc, Minneapolis, Minn) and tried to make it more
independent of the patients’ procoagulant status.
Patients and methods
The ACT II/ECT coagulation measurement is based on a
mechanical method of clot detection. The reagent is pipetted
into the bottom of the cartridges where originally the kaolin
for activated clotting time measurement is placed. After inser-
tion of the plastic flags, the blood sample is placed into the
blood chamber. After an automated period of incubation, the
flags are moved in the device. Clot formation is confirmed by
optical detection of inhibition of the flag movement.
According to a standard calibration curve, the measured time
for clot formation is related to a defined anticoagulant con-
centration. Tests are performed in duplicate in double car-
tridges.
Preparation of the cartridges and ecarin concentra-
tions. HEPES buffer was prepared as follows: 50 mL of
CaCl2 in a concentration of 0.1 mol/L + 40 mL of HEPES
buffer in a concentration of 1 mol/L + 4 mL of 5% bovine
serum albumin + 106 mL H2O was titrated to a pH of 7.0.
Then, 50 U of lyophilized ecarin (Loxo GmbH, Heidelberg,
Germany) was dissolved in 2.5 mL of the solution of HEPES
buffer. This resulted in an ecarin concentration of 20 U in the
stock solution. Concentrations of 10 U and 5 U were achieved
by further dilution of this solution.
The reaction chamber of the blank cartridges (Medtronic,
Inc) was filled with 75 µL of the ecarin reagent and the flags
were inserted. Then 75 µL of standard human plasma
(Behringwerke, Marburg, Germany) and 75 µL of citrated
whole blood were placed into the blood chamber and the test
was started.
In vitro setup. After informed consent, citrated whole
blood samples were collected from 5 healthy volunteers for
the in vitro setup (3 men and 2 women, aged 35–46 years).
The samples were spiked with the following concentrations
of r-hirudin (Refludan; Hoechst, Frankfurt, Germany), 0, 1,
2, 3, 4, and 5 µg/mL, to establish a standard calibration
curve.
After the final ecarin concentration was determined, in a
second part of the in vitro setup, the within-assay variance of
the final preparation of 5 U/mL ecarin reagent was examined
by 5× duplicate measurements of the same sample for r-
hirudin concentrations of 1 µg/mL and 5 µg/mL.
Furthermore, the stability of the prepared and stored
cuvettes was investigated. Therefore, the ecarin was placed in
the cartridge, and the flag was inserted and overlaid with the
plasma. Afterward, the samples were stored at –80°C. The
cartridges were defrosted after a period of 1, 2, 4, and 12
weeks. Measurements were performed in citrated whole
blood samples spiked with 1 and 5 µg/mL concentrations of
r-hirudin and compared with the results of freshly prepared
ecarin cartridges. Each measurement was performed in 5×
duplicate measurements.
In addition, the influence of variations in hematocrit value,
platelet count, and plasmatic coagulation factors on the test
results were assessed. Therefore, the samples were prepared
according to the following:
• Three ranges of hematocrit (20%, 30%, and 60%)
obtained by centrifugation and adjustment of the plasma
fraction
• Three concentrations of platelets (100 · 103/mL, 50 ·
103/mL, and 30 · 103/mL) obtained by centrifugation of
platelet-rich plasma and adjusted to the desired value
with platelet-poor plasma
• Three different concentrations of procoagulants (50%,
30%, and 10% of the initial value) obtained by substitu-
tion of platelet-poor plasma with adequate volumes of a
5% solution of albumin
In vivo setup. The in vivo investigation was performed
with the ecarin reagent concentrations of 5 and 10 U/mL.
After approval by the local ethics committee and informed
consent, 5 patients with HIT II who underwent cardiac
surgery (coronary artery bypass grafting, n = 2; aortic valve
replacement, n = 2; aortic valve replacement + bypass graft-
ing, n = 1) with r-hirudin as the anticoagulant were included
in the investigation.
The r-hirudin regimen for anticoagulation of CPB consisted
of a bolus of 0.25 mg/kg of body weight for the patient and 0.20
mg/kg of body weight in the priming solution. When a hirudin
concentration of 3.5 to 4.0 µg/mL was achieved, CPB was ini-
tiated. This concentration was maintained by an infusion of r-
hirudin that was adjusted to the actual measured level. The r-
hirudin level was monitored with the TAS analyzer. In all
patients, aprotinin, the kallikrein inhibitor and antifibrinolytic
Fig 1.  Calibration curve for r-hirudin and ACT II/ECT using
three different concentrations of ecarin reagent. ECT, Ecarin
clotting time; cHir, concentration of hirudin.
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agent, was used according to a high-dose regimen with a bolus
of 2 × 106 kIU for the patient and in the priming solution and a
constant infusion of 500,000 kIU/h during CPB.
Citrated whole blood samples were taken every 20 minutes
during CPB and for 2 hours after CPB.
Chromogenic reference test.  The chromogenic test was
performed in plasma. The plasma sample was incubated with
tris (hydroxymethyl) aminomethane hexadimethrine bromide
(Polybrene) buffer, S-2238 substrate (Chromogenix, Essen,
Germany), and thrombin reagent (Boehringer, Mannheim,
Germany) and measured with a COBAS MIRA analyzer
(Behringwerke, Marburg, Germany) at an extinction value of
405 nm.
Statistical analysis.  Statistical analysis of the influence of
variations of the hematocrit value, platelet count, and plas-
matic coagulation factors was performed by means of analy-
sis of variance with the Scheffé test. A P value of < 0.01 was
defined as statistically significant. The TAS/ECT and labora-
tory chromogenic results were analyzed by the Pearson cor-
relation coefficient test.
Results
Standard calibration curves.  The standard calibra-
tion curves of all three ecarin reagents revealed linearity
to r-hirudin concentrations from 0 to 5 µg/mL. However,
the range between the 0 and 5 µg/mL r-hirudin of 40 sec-
onds in the ecarin concentration of 20 U/mL was consid-
ered to be too narrow for precise differentiation of the r-
hirudin concentrations. In contrast, with the use of the 10
and 5 U/mL ecarin reagents, the test range was spread
over ranges of 80 and 140 seconds, respectively (Fig 1).
Therefore, only these reagent concentrations were used
for the in vivo evaluation.
In vivo evaluation.  CPB ranged from 55 to 125
minutes with a mean of 75 ± 23 minutes. The initial
r-hirudin requirement ranged from 0.25 to 0.45
mg/kg of body weight with a mean of 0.28 ± 0.6
mg/kg of body weight. The total r-hirudin require-
ment ranged from 0.65 to 1.50 mg/kg of body weight
with a mean of 0.78 ± 0.18 mg/kg.
The hematocrit values ranged from 22% to 48%
(mean 27% ± 8.7%).
No clot formation was found in the heart-lung
machine after termination of CPB. In the first 24 hours,
the postoperative blood loss of the patients ranged from
150 to 550 mL with a mean of 325 ± 75 mL.
The chromogenically measured r-hirudin plasma
concentration ranged from 0.02 to 10 µg/mL. The cor-
relation of the 5 U/mL ecarin reagent to the chro-
mogenic method was 0.87 (Fig 2, A), and the correla-
tion of the 10 U/mL ecarin reagent was 0.67 (Fig 2, B).
In vitro evaluation of the final assay. The ecarin
concentration of 5 U/mL was evaluated as the final
concentration of the test. The within-assay variation
coefficient measured for r-hirudin concentrations of 1
and 5 µg/mL was less than 5% (Table I). The differ-
ence between measurements obtained from the
cuvettes stored for 12 weeks at –80°C and the fresh-
ly prepared cuvettes was below 5% (Table II). The
test was not significantly influenced by variations of
the hematocrit value from 60% to 20% (Fig 3, A).
Moreover, the test results were not influenced by a
reduction of the platelet count to 30,000/mL (Fig 3,
B) and a reduction of the plasmatic coagulation fac-
tors to 10% (Fig 3, C).
Discussion
Currently used whole blood point-of-care monitoring
assays, such as the activated clotting time or the acti-
vated partial thromboplastin time, are not reliable for
monitoring anticoagulation with r-hirudin during
CPB.4 Therefore, the use of r-hirudin for anticoagula-
tion of CPB in patients with HIT II has been largely
restricted because of the lack of a reliable monitoring
technique in the operating room. ACT II/ECT is easy to
measure and enables hirudin levels to be controlled to
maintain sufficient anticoagulation during CPB.
Fig 2.  Correlation of the ACT II/ECT to the plasmatic chro-
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The ACT II device is produced for measurement of
the kaolin activated clotting time with prepared car-
tridges. This global coagulation assay is mainly used
for monitoring anticoagulation with unfractionated
heparins during CPB or angioplasty in the heart
catheterization laboratory. However, with the use of
blank cartridges and the addition of the originally plas-
ma-based Heptest reagent (Boehringer), an anti-Xa
activity test is created for monitoring the levels of low
molecular weight heparins as well as unfractionated
heparins in citrated whole blood.7 The addition of
ecarin into the reaction chamber of the cartridge pro-
vides an easy-to-perform ECT assay for monitoring
direct thrombin inhibitors such as r-hirudin.
The ACT II device appears to be preferable to other
options for adapting other more specific coagulation
tests, as tests are performed in double cartridges and the
low-range cartridge needs a volume of only 200 µL in
comparison with 2 mL needed in other devices.
Moreover, the automated period is integrated. As the
reagents are major contributors to the cost of the assay,
reducing the volumes of reagents needed effectively
reduces the costs of the tests.
The ECT assay is based on the principle of ecarin-
induced conversion of prothrombin to meizothrombin.
Meizothrombin inhibits hirudin by the formation of a
stable 1:1 complex. After the neutralization of r-
hirudin, coagulation is initiated (in a slower reaction
when compared with thrombin) by meizothrombin
itself via the conversion of fibrinogen to fibrin.
Therefore, a coagulation time can be related to a
determined hirudin level. However, it is important to
provide high fibrinogen and prothrombin levels for
precise measurement of particularly higher (>2
µg/mL) r-hirudin levels.5,6 Because procoagulants are
diluted and depleted by contact activation on the sur-
faces of the extracorporeal system during CPB, the
use of the ACT II/ECT enables sufficient fibrinogen
and prothrombin levels to be ensured by 1:1 dilution
of the blood sample with standard human plasma.
However, because of this procedure, the r-hirudin con-
centration in the sample is halved. Therefore, the use
of the original 20 U/mL ecarin solution led to a too
narrow running time to ascertain the r-hirudin levels
Table I.  Within-assay variability of the final ACT II/ECT assay
cHir (µg/mL) ECT Mean SD VC
1 85 87 85 88 87 90 86 86 85 88 86.7 1.64 1.90
5 206 212 205 212 196 204 204 212 210 208 206.8 4.80 0.23
cHir, Concentration of hirudin; SD, standard deviation; VC, variation coefficient.
Fig 3.  Influence of variations in the hematocrit value, platelet
count, and coagulation factors on ACT II/ECT assay. ECT,





between 0 and 5 µg/mL (approximately 30 seconds,
Fig 1). Therefore, the ecarin concentration was
reduced to prolong the coagulation time of the assay.
The 5 U/mL concentration of ecarin demonstrated lin-
earity for a r-hirudin concentration of up to 5 µg/mL,
which is above the recommended concentration for
anticoagulation of CPB4 and demonstrated an excel-
lent correlation to the non-hematocrit corrected values
of the plasmatic chromogenic test (r = 0.87).
However, although the correlation of the ACT II/ECT
was excellent (0.87), the scattering needs an explana-
tion (Fig 2, A). The chromogenic test was performed
in plasma and not corrected for the actual hematocrit
value. Therefore, the results were influenced by the
large variation in the hematocrit value (22%-48%),
which reduced the agreement between the two assays.
The test range of 140 seconds between the 0 and 5
µg/mL values (200 seconds total) was evaluated as
optimal in terms of quick results and better differenti-
ation of the r-hirudin concentrations. With this con-
centration, the assay revealed reproducible and reli-
able measurements of the r-hirudin level, even in
cases of marked hemodilution, decrease in platelet
count, and loss of coagulation factors, which particu-
larly occur during prolonged CPB.
Because the ecarin solution remains stable at –80°C,
as has been demonstrated previously, the test cartridges
can be prepared and stored.4 Moreover, the standard
human plasma can be overlaid after insertion of the
flags before the cartridges are frozen. This ensures that
the cartridges can be stored for at least 3 months and
are ready to use if needed (Table II). As the incubation
period is automated in contrast to the original method,
only one working step is necessary in the operating
room, and it can be easily performed by the anesthetist
or perfusionist during the operation.
However, with regard to the inter-individual varia-
tions in the r-hirudin response, as seen in the calibration
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curves (Fig 1), the establishment of an individual cali-
bration curve before application of r-hirudin is recom-
mended for precise measurement. This can be quickly
(<15 minutes) achieved by the use of deep frozen pre-
viously pipetted solutions of r-hirudin.
However, if CPB has to be established immediately,
on an emergency basis, a value of 180 to 200 seconds
appears to be appropriate to initiate CPB. According to
the calibration curve, this value represents a concentra-
tion of approximately 4 µg/mL of r-hirudin. Therefore,
after the initiation of CPB, the individual calibration
curve can be quickly constructed by use of a previous-
ly obtained whole blood sample and the concentration
adjusted to the individual demands by up- or down-reg-
ulation of the continuous r-hirudin infusion.
We conclude that the ACT II–modified ECT is a reli-
able, easy-to-perform, and inexpensive point-of-care
assay for monitoring r-hirudin during CPB. Thus, it
may contribute to a wider use of r-hirudin and to the
safer management, particularly during CPB, of patients
with HIT II. However, further investigations with larg-
er numbers of patients are necessary for a final clinical
evaluation of the assay.
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